🩺 Lenvaxen 10 mg (Lenvatinib) Capsules

Manufactured by: Everest Pharmaceuticals Ltd.
Distributed by: NP Molecule
Strength: 10 mg per capsule
Formulation: Lenvatinib Mesylate INN equivalent to Lenvatinib 10 mg
Packaging: 30 Capsules per bottle
Route of administration: Oral

🔬 What is Lenvaxen (Lenvatinib)?

Lenvaxen 10 mg is a targeted oral anticancer medication containing Lenvatinib, a multikinase inhibitor that blocks various signaling pathways involved in tumor growth and angiogenesis (formation of new blood vessels that supply cancer cells).

It is primarily used in cancers that are resistant to standard therapies or are in advanced, unresectable stages.

🧪 Mechanism of Action

Lenvatinib inhibits multiple receptor tyrosine kinases (RTKs) involved in:

• Tumor proliferation

• Angiogenesis

• Cancer cell survival

Targeted receptors include:

• VEGFR1–3: Vascular endothelial growth factor receptors

• FGFR1–4: Fibroblast growth factor receptors

• PDGFRα: Platelet-derived growth factor receptor alpha

• RET and KIT: Oncogenic signaling proteins

By inhibiting these kinases, Lenvatinib reduces blood supply to tumors and slows cancer cell replication.

💊 Indications for Use

Lenvaxen 10 mg is indicated for the treatment of:

1. Differentiated Thyroid Cancer (DTC)

   • In patients with progressive disease that is radioactive iodine-refractory (RAI-refractory)

2. Unresectable Hepatocellular Carcinoma (HCC)

   • As a first-line therapy in adults

3. Advanced Renal Cell Carcinoma (RCC)

   • In combination with everolimus following one prior anti-angiogenic therapy

4. Endometrial Carcinoma

   • In combination with pembrolizumab for patients with advanced disease after prior systemic therapy (non–microsatellite instability-high [MSI-H] or mismatch repair deficient [dMMR] tumors)

📋 Dosage & Administration

Dosage varies by condition and patient body weight.

• Thyroid Cancer / RCC (with everolimus):

  • 24 mg once daily (or dose-adjusted per toxicity)

• Hepatocellular Carcinoma (HCC):

  • 12 mg once daily (if weight ≥60 kg)

  • 8 mg once daily (if weight <60 kg)

• Endometrial Carcinoma (with pembrolizumab):

  • 20 mg once daily

Administration tips:

• Take at the same time each day, with or without food.

• Swallow whole with water.

• If a dose is missed, take it as soon as remembered unless it’s near the time for the next dose.

⚠️ Warnings & Precautions

1. Hypertension – Monitor blood pressure before and during treatment.

2. Hepatotoxicity – Liver function tests recommended regularly.

3. Renal Impairment & Proteinuria – May cause or worsen kidney dysfunction.

4. QT Interval Prolongation – Use with caution in patients with cardiac risk.

5. Hemorrhagic Events & GI Perforation – Rare but serious; monitor symptoms closely.

6. Reproductive Toxicity – May cause fetal harm; contraception required.

🧾 Adverse Reactions (Common ≥20%)

• Hypertension

• Diarrhea

• Fatigue

• Weight loss

• Nausea

• Anorexia

• Arthralgia and muscle pain

• Stomatitis

• Rash or hand-foot skin reaction

🔄 Drug Interactions

• CYP3A4 inhibitors/inducers may affect plasma levels of Lenvatinib.

• Concurrent use with QT-prolonging agents should be avoided.

• Monitor when combining with immunotherapies or other kinase inhibitors.

🤝 Patient Counseling Information

• Regular monitoring (blood pressure, liver/kidney function) is critical.

• Inform physician of all medications and supplements.

• Pregnant or breastfeeding women should avoid use.

• Notify your doctor immediately if you experience unusual bleeding, chest pain, or swelling.

📦 Product Details

• Brand Name: Lenvaxen

• Generic Name: Lenvatinib

• Storage: Store below 30°C, protect from moisture and light

• Shelf Life: Refer to packaging for expiry

📱 Contact & Ordering Information

NP Molecule
📍 Sector-14, Uttara, Dhaka-1230
📞 +8801844288466
📧 npmolecule23@gmail.com
🌐 www.npmoleculeoncology.com

📲 Scan QR code on packaging to verify authenticity and access detailed information.